Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GPR39 | O43194 | 1/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916892 | 1.00 | TRPV1 (0.59) | TRPV1TRPM8RXFP1GPR39LIPC | |
| SCHEMBL5917120 | 1.00 | TRPV1 (0.59) | TRPV1TRPM8RXFP1GPR39LIPC | |
| SCHEMBL5917049 | 0.99 | TRPV1 (0.58) | TRPV1TRPM8RXFP1GPR39LIPC | |
| SCHEMBL5917081 | 0.97 | TRPV1 (0.60) | TRPV1TRPM8GPR39LIPCLIPG | |
| SCHEMBL5916942 | 0.97 | TRPV1 (0.60) | TRPV1TRPM8GPR39LIPCLIPG | |
| SCHEMBL5916919 | 0.97 | TRPV1 (0.60) | TRPV1TRPM8GPR39LIPCLIPG | |
| SCHEMBL5916899 | 0.86 | RXFP1 (0.42) | TRPV1TRPM8RXFP1LIPCLIPG | |
| SCHEMBL5916938 | 0.85 | TRPV1 (0.55) | TRPV1TRPM8 | |
| SCHEMBL5916973 | 0.85 | TRPV1 (0.48) | TRPV1RXFP1GPR39LIPCLIPG | |
| SCHEMBL5917119 | 0.84 | TRPV1 (0.47) | TRPV1RXFP1GPR39LIPCLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883632-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006116563-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | TRPV1, HRH2, TRPA1 | TRPV1 1/4885TRPM8 66/4885RXFP1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.